TITLE

"TOASTER SIZE" DEVICE MEASURES CD4 COUNT, HELPING HIV TREATMENT IN RURAL AREAS

PUB. DATE
September 2004
SOURCE
Clinical Infectious Diseases;9/1/2004, Vol. 39 Issue 5, preceding p609
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Scientists at the University of Texas have developed a portable HIV testing laboratory that experts say should speed up diagnosis and treatment of AIDS in remote regions of the world. The device, smaller than a toaster, measures the level of patients' CD4 cells within 15 mm and works on rechargeable batteries. "Essentially it's a digital reader device, a very small, miniaturized laboratory," Richard Hawkins, head of LabNow Inc., the company created to manufacture and sell the product, told Reuters Television.
ACCESSION #
14175542

 

Related Articles

  • Comparison of susceptibility to SIVmac239 infection between CD4+ and CD4+8+ T cells. Takahashi, M.; Ido, E.; Uesaka, H.; Fukushima, T.; Ibuki, K.; Miura, T.; Hayami, M.; Takahashi, H. // Archives of Virology;Aug2005, Vol. 150 Issue 8, p1517 

    CD4-bearing T cells are the primary targets for human immunodeficiency virus type 1(HIV-1)/simian immunodeficiency virus (SIV) infection. However, it is unclear whether the susceptibility of CD4-bearing T cells including CD4 single positive and CD4/8 double positive T cells to HIV/SIV infection...

  • Has Human Immunodeficiency Virus Become More Virulent? Dorrucci, Maria; Phillips, Andrew // Clinical Infectious Diseases;5/1/2009, Vol. 48 Issue 9, p1293 

    The article reports on the study on the initial CD4 cell counts among HIV seroconverters during the course of the HIV epidemic in the U.S. It states that ascertainment of HIV seroconversion through regular testing of all military personnel and early CD4 cell count assessments in all infected...

  • Increased CD4 and CCR5 Expression and Human Immunodeficiency Virus Type 1 Entry in CD40 Ligand-Stimulated Macrophages. Bergamini, Alberto; Bolacchi, Francesca; Pesce, Caterina Delfina; Carbone, Marica; Cepparulo, Mario; Demin, Flavio; Rocchi, Giovanni // Journal of Infectious Diseases;6/1/2002, Vol. 185 Issue 11, p1567 

    The effects of a soluble trimeric CD40 ligand (CD40L) agonist on the expression of CD4 and CCR5 and on human immunodeficiency virus (HIV) type 1 entry into and replication in human macrophages were investigated. CD40L increased the number of CD4 and CCR5 antibody-binding sites and the percentage...

  • Regulatory T Cell Suppression of Gag-Specific CD8+ T Cell Polyfunctional Response After Therapeutic Vaccination of HIV-1-Infected Patients on ART. Macatangay, Bernard J. C.; Szajnik, Marta E.; Whiteside, Theresa L.; Riddler, Sharon A.; Rinaldo, Charles R. // PLoS ONE;2010, Vol. 5 Issue 3, p1 

    We tested the hypothesis that therapeutic vaccination against HIV-1 can increase the frequency and suppressive function of regulatory, CD4+ T cells (Treg), thereby masking enhancement of HIV-1-specific CD8+ T cell response. HIV-1-infected subjects on antiretroviral therapy (N = 17) enrolled in a...

  • Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Finzi, Diana; Blankson, Joel; Siliciano, Janet D.; Margolick, Joseph B.; Chadwick, Karen; Pierson, Theodore; Smith, Kendall; Lisziewicz, Julianna; Lori, Franco; Flexner, Charles; Quinn, Thomas C.; Chaisson, Richard E.; Rosenberg, Eric; Walker, Bruce; Gange, Stephen; Gallant, Joel; Siliciano, Robert F. // Nature Medicine;May99, Vol. 5 Issue 5, p512 

    Combination therapy for HIV-1 infection can reduce plasma virus to undetectable levels, indicating that prolonged treatment might eradicate the infection. However, HIV-1 can persist in a latent form in resting CD4[sup +] T cells. We measured the decay rate of this latent reservoir in 34 treated...

  • Effects of Virologic Rebound on CD4 Cell Counts. Bahrani, Ashkan; Ramaswamy, Ramesh; Oldfield III, Edward C. // Clinical Infectious Diseases;4/15/2001, Vol. 32 Issue 8, p1231 

    Presents information on a study which examined the effects of virologic rebound on CD4 cell counts in HIV-infected patients. Methodology; Results of the study; Discussion.

  • Is the clinical course of HIV-1 changing? Cohort study. Sinicco, A.; Fora, R. // BMJ: British Medical Journal (International Edition);04/26/97, Vol. 314 Issue 7089, p1232 

    Assesses whether the clinical course of HIV infection has changed from 1985 to 1995. Disease progression; Speed of CD4 cell decline in patients with recently acquired HIV infection.

  • Effect of HIV-1 Subtype on Virologic and Immunologic Response to Starting Highly Active Antiretroviral Therapy. Geretti, Anna Maria; Harrison, Linda; Green, Hannah; Sabin, Caroline; Hill, Teresa; Fearnhill, Esther; Pillay, Deenan; Dunn, David // Clinical Infectious Diseases;5/1/2009, Vol. 48 Issue 9, p1296 

    Background. It has been proposed that subtype-related human immunodeficiency virus type 1 (HIV-1) variability may influence virologic and immunologic responses to highly active antiretroviral therapy (HAART). Studies to date, however, have described treatment outcomes predominantly in persons...

  • HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Pitcher, Christine J.; Quittner, Claudia; Peterson, Dolores M.; Connors, Mark; Koup, Richard A.; Maino, Vernon C.; Picker, Louis J. // Nature Medicine;May99, Vol. 5 Issue 5, p518 

    The role of HIV-1-specific CD4[sup +] T-cell responses in controlling HIV-1 infection remains unclear. Previous work has suggested that such cells are eliminated in the early stages of infection in most subjects, and thus cannot substantially contribute to host defense against HIV-1. Here, using...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics